Fig. 2.

Kaplan–Meier survival analyses for morbidity. a. Time to first renal, cardiac or stroke event, or death for agalsidase alfa–treated patients from FOS and untreated (placebo arm) patients in a study by Banikazemi et al. [20]. b. Age at first event for treated patients from FOS and untreated patients from a study by Schiffmann et al. [21]. BL, baseline; CI, confidence interval; FOS, Fabry Outcome Survey. Right panel of Fig. 2a adapted with permission from Banikazemi et al. [20]. Right panel of Fig. 2b was adapted from Schiffmann et al. [21] with permission from Oxford University Press. *Cumulative probability function of these events. ^†Time to first composite event on or after start of agalsidase alfa. ^‡Time on study to first composite event. ^§Age at first composite event on or after start of agalsidase alfa. ^∥Age at first composite event.